New targeted drug safety check for advanced breast cancer in india

NCT ID NCT06429761

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 4 study is testing the safety of trastuzumab deruxtecan, a targeted antibody-drug combination, in 100 Indian adults with advanced HER2-positive breast cancer that cannot be removed by surgery or has spread. Participants have already received at least one prior anti-HER2 treatment. They will receive the drug by IV every 3 weeks for up to 9 cycles. The main goal is to track side effects and ensure the drug is safe in this specific population.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: trastuzumab deruxtecan (a targeted antibody-drug combination)
What this could lead to: If successful, this could confirm that trastuzumab deruxtecan is safe for Indian patients with advanced HER2+ breast cancer, supporting its use as a standard treatment option.
What could go wrong: This is a single-arm, open-label study focused on safety, not efficacy. Side effects like nausea, fatigue, or lung inflammation may occur, and results may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Research Site
RECRUITING

Bangalore, 560017, India
Research Site
RECRUITING

Delhi, 110029, India
Research Site
RECRUITING

Kochi, 682041, India
Research Site
RECRUITING

Mumbai, 400012, India
Research Site
RECRUITING

Pune, 411028, India
Research Site
RECRUITING

Varanasi, 221005, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.